Quanterix Corp
No SEC Form 4 filings for $QTRX in the last 30 days.
See all $QTRX insider activity →Quanterix (QTRX) announced that China's NMPA approved its HD-X and SR-X instruments and four neurology biomarker kits via partner Innovita, expanding its IVD access in China. The approvals include kits for p-Tau 217, GFAP, p-Tau 181, and NfL. The company aims to convert research tech into clinical IVD revenue through regional partners.
Quanterix (QTRX) announced global availability of its PhenoCode 2.0 Molecular Barcoding Kit and plans to ship TIME and high-plex ADC panels in Q4 2026. The company also launched Accelerator Laboratory Services for custom ADC panel development. Quanterix aims to advance spatial biology content, supported by its Content Innovation Engine and integration of Akoya Biosciences' platform.
Trinity Biotech (TRIB) surged 16% after launching Trinovium, a subsidiary for AI data center liquid-cooling solutions. Quanterix (QTRX) rose 6% following CFO appointment. Recon Technology (RCON) gained 27% in after-hours trading after a sharp intraday decline. All three stocks have seen significant declines year-to-date.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning QTRX (Quanterix Corp). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent QTRX coverage spans earnings, market movers and insider activity.
Positive regulatory clearance opens a new revenue stream in the Chinese market.
The product announcements may modestly boost demand for Quanterix's platforms but lack immediate revenue guidance.
Leadership changes aim to stabilize execution of neurological‑diagnostic tests.
The hire signals a strategic push in diagnostics, likely supporting revenue growth.
The guidance reset and added commercial leadership and reorg are likely to pressure near-term sentiment while setting up a 2027 inflection narrative.
AlphAI scores every news story that mentions QTRX with an AI model for sentiment and relevance, and aggregates insider trades from Quanterix Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Quanterix (QTRX) announced that China's NMPA approved its HD-X and SR-X instruments and four neurology biomarker kits via partner Innovita, expanding its IVD access in China. The approvals include kits for p-Tau 217, GFAP, p-Tau 181, and NfL. The company aims to convert research tech into clinical IVD revenue through regional partners.
1 min readQuanterix (QTRX) announced global availability of its PhenoCode 2.0 Molecular Barcoding Kit and plans to ship TIME and high-plex ADC panels in Q4 2026. The company also launched Accelerator Laboratory Services for custom ADC panel development. Quanterix aims to advance spatial biology content, supported by its Content Innovation Engine and integration of Akoya Biosciences' platform.
2 min readTrinity Biotech (TRIB) surged 16% after launching Trinovium, a subsidiary for AI data center liquid-cooling solutions. Quanterix (QTRX) rose 6% following CFO appointment. Recon Technology (RCON) gained 27% in after-hours trading after a sharp intraday decline. All three stocks have seen significant declines year-to-date.
2 min readQuanterix Corporation appointed Geoff Albrecht as senior vice president and general manager of Diagnostics. Albrecht, with over 25 years of experience at Quest Diagnostics, will lead the development of Quanterix's Diagnostics strategy, focusing on Alzheimer’s Disease Diagnostics. Quanterix aims to scale its Diagnostics portfolio into a significant revenue driver, reporting to CEO Everett Cunningham.
1 min readQuanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.
7 min readQuanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.
6 min readDONNELLY WILLIAM P purchased 99,400 indirectly-held shares of Quanterix Corp (QTRX) at an average of $2.88 ($2.75–$2.93, $0.29M total) across 2 trades over 2026-08-12 to 2026-08-13.
2 min readQuanterix (NASDAQ:QTRX) reported Q2 cash use of $5.7M and cash of $96.9M. Simoa revenue was $20.6M, Spatial $12.3M, and GAAP gross margin 38.5%. Management guided Q3 revenue flat to slightly above Q2 and cited Akoya integration, $85M annualized savings, and commercial reorganization. FDA timing for LucentAD Complete is targeted for late 2026.
6 min readQuanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2026 Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends
6 min readMeadows Benjamin (Chief Commercial Officer) purchased 3,500 shares of Quanterix Corp (QTRX) at $2.77 on 2026-05-12.
2 min read
